Verseau Therapeutics Verseau Therapeutics
  • About
    • Team
    • Investors
    • Partners
  • Science
  • Pipeline
  • News
  • Contact
  • Careers

News

3SBio Selects Verseau’s PSGL-1-targeted Antibody VTX-0811 as First Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration
November 18, 2019

Verseau Therapeutics Appoints Tim Smith as Chief Business Officer
November 13, 2019

Verseau Launches with $50 Million to Develop First-in-Class Macrophage-Targeted Immunotherapies and Appoints George Golumbeski as Chairman of the Board
October 21, 2019

3SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies
February 11, 2019

© 2021 Copyright, Verseau Therapeutics, Inc. All Rights Reserved.
Logo
  • About
    • Team
    • Investors
    • Partners
  • Science
  • Pipeline
  • News
  • Contact
  • Careers